Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label sacubitril/valsartan in pediatric heart failure (Japan, PANORAMA-HF extension)
jRCT2080224897Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of sacubitril/valsartan. Started Sep 2019; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on jRCT2080224897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224897.